| Original language | English (US) |
|---|---|
| Pages (from-to) | 1541-1542 |
| Number of pages | 2 |
| Journal | JACC: Cardiovascular Interventions |
| Volume | 11 |
| Issue number | 15 |
| DOIs | |
| State | Published - Aug 13 2018 |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Reply : Strong Bias Toward Performing Percutaneous Coronary Intervention in Patients With Chronic Total Occlusion Despite Lack of Important Benefit at a Very High Cost and Risk to the Patient. / Tajti, Peter; Burke, M. Nicholas; Karmpaliotis, Dimitri; Alaswad, Khaldoon; Werner, Gerald S.; Azzalini, Lorenzo; Carlino, Mauro; Patel, Mitul; Mashayekhi, Kambis; Egred, Mohaned; Krestyaninov, Oleg; Khelimskii, Dmitrii; Nicholson, William J.; Ungi, Imre; Galassi, Alfredo R.; Banerjee, Subhash; Brilakis, Emmanouil S.
In: JACC: Cardiovascular Interventions, Vol. 11, No. 15, 13.08.2018, p. 1541-1542.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Reply
T2 - Strong Bias Toward Performing Percutaneous Coronary Intervention in Patients With Chronic Total Occlusion Despite Lack of Important Benefit at a Very High Cost and Risk to the Patient
AU - Tajti, Peter
AU - Burke, M. Nicholas
AU - Karmpaliotis, Dimitri
AU - Alaswad, Khaldoon
AU - Werner, Gerald S.
AU - Azzalini, Lorenzo
AU - Carlino, Mauro
AU - Patel, Mitul
AU - Mashayekhi, Kambis
AU - Egred, Mohaned
AU - Krestyaninov, Oleg
AU - Khelimskii, Dmitrii
AU - Nicholson, William J.
AU - Ungi, Imre
AU - Galassi, Alfredo R.
AU - Banerjee, Subhash
AU - Brilakis, Emmanouil S.
N1 - Funding Information: Please note: Dr. Burke has received consulting and speaker honoraria from Abbott Vascular and Boston Scientific. Dr. Karmpaliotis has received speaker honoraria from Abbott Vascular, Medtronic, Boston Scientific, and Vascular Solutions. Dr. Alaswad has received consulting fees from Terumo and Boston Scientific; and has been an (unpaid) consultant for Abbott Laboratories. Dr. Werner has received speaker honoraria for Asahi Intecc, Abbott Vascular, Biosensors, and Terumo; and has been the principal investigator of a randomized trial on the benefit of CTO PCI versus medical therapy conducted by the EURO CTO Club sponsored by Asahi Intecc and Biosensors. Dr. Patel has received consulting honoraria from Abbott Vascular. Dr. Mashayekhi has received honoraria from Asahi Intecc. Dr. Nicholson has been a proctor or served on the Speakers Bureau/Advisory Board of Abbott Vascular, Boston Scientific, and Asahi Intecc; and holds intellectual property in Vascular Solutions. Dr. Banerjee has received research grants from Gilead and The Medicines Company; received consultant/speaker honoraria from Covidien and Medtronic; holds intellectual property in HygeiaTel; and his spouse has ownership in DCARE Global. Dr. Brilakis has received consulting/speaker honoraria from Abbott Vascular, ACIST Medical Systems, Amgen, Asahi Intecc, CSI, Elsevier, GE Healthcare, Medicure, Medtronic, and Nitiloop; received research support from Boston Scientific and Osprey; served on the board of directors of Cardiovascular Innovations Foundation; and served on the board of trustees of Society of Cardiovascular Angiography and Interventions. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
PY - 2018/8/13
Y1 - 2018/8/13
UR - http://www.scopus.com/inward/record.url?scp=85050669831&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050669831&partnerID=8YFLogxK
U2 - 10.1016/j.jcin.2018.05.015
DO - 10.1016/j.jcin.2018.05.015
M3 - Letter
C2 - 30093064
AN - SCOPUS:85050669831
VL - 11
SP - 1541
EP - 1542
JO - JACC: Cardiovascular Interventions
JF - JACC: Cardiovascular Interventions
SN - 1936-8798
IS - 15
ER -